Investor Presentaiton

A focused global biopharma company with bold ambitions Ambition and Purpose To unite science, technology, and talent to get ahead of disease together Growth Highly attractive medium-term¹ target for sales and adjusted operating profit growth of >5% and >10% CAGR² Flexibility Strengthened balance sheet, creating new flexibility to invest in growth and innovation GSK 1. Medium-term is 2021-2026, excluding COVID-19 solutions 2. At constant exchange rates (CER) LO 5

View entire presentation